Cargando…
The Use of IGF-I to Monitor Long-Acting Growth Hormone Therapy—Timing is an Art…
Autores principales: | Bidlingmaier, Martin, Schilbach, Katharina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063241/ https://www.ncbi.nlm.nih.gov/pubmed/33524146 http://dx.doi.org/10.1210/clinem/dgab016 |
Ejemplares similares
-
Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly
por: Clemmons, David R., et al.
Publicado: (2023) -
Growth Hormone Research Society perspective on the development of
long-acting growth hormone preparations
por: Christiansen, Jens Sandahl, et al.
Publicado: (2016) -
Differences in the Distribution of IGF-I Concentrations Between European and US Populations
por: Bidlingmaier, Martin, et al.
Publicado: (2022) -
Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits
por: Bielohuby, Maximilian, et al.
Publicado: (2014) -
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2022)